In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
- Autores
- Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; Castañeda Méndez, Paulo; Jaime-Villalón, Diego; Gales, Ana; Munita, Jose; Villegas, Maria
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America
Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia
Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia
Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia
Fil: Pallares, Cristian. Universidad El Bosque; Colombia
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México
Fil: Jaime-Villalón, Diego. Hospital San Angel; México
Fil: Gales, Ana. Universidade de Sao Paulo; Brasil
Fil: Munita, Jose. No especifíca;
Fil: Villegas, Maria. Universidad El Bosque; Colombia - Materia
-
Ceftazidime/Avibactam
Enterobacterales
Antibiotic susceptibility - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/109947
Ver los metadatos del registro completo
id |
CONICETDig_c252f494893952a60d902605ffeb586e |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/109947 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American CountriesAppel, Tobias ManuelMojica, Maria FernandaDe La Cadena, ElsaPallares, CristianRadice, Marcela AlejandraCastañeda Méndez, PauloJaime-Villalón, DiegoGales, AnaMunita, JoseVillegas, MariaCeftazidime/AvibactamEnterobacteralesAntibiotic susceptibilityhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin AmericaFil: Appel, Tobias Manuel. Universidad El Bosque; ColombiaFil: Mojica, Maria Fernanda. Universidad El Bosque; ColombiaFil: De La Cadena, Elsa. Universidad El Bosque; ColombiaFil: Pallares, Cristian. Universidad El Bosque; ColombiaFil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Castañeda Méndez, Paulo. Hospital Médica Sur; MéxicoFil: Jaime-Villalón, Diego. Hospital San Angel; MéxicoFil: Gales, Ana. Universidade de Sao Paulo; BrasilFil: Munita, Jose. No especifíca; Fil: Villegas, Maria. Universidad El Bosque; ColombiaMDPI2020-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/109947Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-72079-6382CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics9020062info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2079-6382/9/2/62info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:23:37Zoai:ri.conicet.gov.ar:11336/109947instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:23:37.885CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
title |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
spellingShingle |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries Appel, Tobias Manuel Ceftazidime/Avibactam Enterobacterales Antibiotic susceptibility |
title_short |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
title_full |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
title_fullStr |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
title_full_unstemmed |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
title_sort |
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries |
dc.creator.none.fl_str_mv |
Appel, Tobias Manuel Mojica, Maria Fernanda De La Cadena, Elsa Pallares, Cristian Radice, Marcela Alejandra Castañeda Méndez, Paulo Jaime-Villalón, Diego Gales, Ana Munita, Jose Villegas, Maria |
author |
Appel, Tobias Manuel |
author_facet |
Appel, Tobias Manuel Mojica, Maria Fernanda De La Cadena, Elsa Pallares, Cristian Radice, Marcela Alejandra Castañeda Méndez, Paulo Jaime-Villalón, Diego Gales, Ana Munita, Jose Villegas, Maria |
author_role |
author |
author2 |
Mojica, Maria Fernanda De La Cadena, Elsa Pallares, Cristian Radice, Marcela Alejandra Castañeda Méndez, Paulo Jaime-Villalón, Diego Gales, Ana Munita, Jose Villegas, Maria |
author2_role |
author author author author author author author author author |
dc.subject.none.fl_str_mv |
Ceftazidime/Avibactam Enterobacterales Antibiotic susceptibility |
topic |
Ceftazidime/Avibactam Enterobacterales Antibiotic susceptibility |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America Fil: Appel, Tobias Manuel. Universidad El Bosque; Colombia Fil: Mojica, Maria Fernanda. Universidad El Bosque; Colombia Fil: De La Cadena, Elsa. Universidad El Bosque; Colombia Fil: Pallares, Cristian. Universidad El Bosque; Colombia Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Microbiología, Inmunología y Biotecnología. Cátedra de Microbiología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Castañeda Méndez, Paulo. Hospital Médica Sur; México Fil: Jaime-Villalón, Diego. Hospital San Angel; México Fil: Gales, Ana. Universidade de Sao Paulo; Brasil Fil: Munita, Jose. No especifíca; Fil: Villegas, Maria. Universidad El Bosque; Colombia |
description |
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which hasshown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 andOctober 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% ofEnterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/109947 Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-7 2079-6382 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/109947 |
identifier_str_mv |
Appel, Tobias Manuel; Mojica, Maria Fernanda; De La Cadena, Elsa; Pallares, Cristian; Radice, Marcela Alejandra; et al.; In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries; MDPI; Antibiotics; 9; 2; 2-2020; 1-7 2079-6382 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3390/antibiotics9020062 info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2079-6382/9/2/62 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614231791501312 |
score |
13.070432 |